Canine Gerosciences™ Framework

Canine Geroscience

LPL-01™ Companion-Care Standard · La Petite Labs — Integrative Aging Biology for Dogs

Preface

Geroscience is the field of study that investigates the intersection of aging, biology, and disease to determine how the biological mechanisms of aging can be leveraged and targeted to improve healthspan — the number of disease-free years. Taking an active approach to modifying the aging process, rather than seeing aging as an inevitable march toward functional decline, represents a paradigm shift in veterinary geriatric care.

The purpose of the canine geroscience framework is to take a scientific deep dive into the hallmarks of aging in dogs — including cellular senescence, oxidative stress, and inflammaging — to explore the molecular mechanisms of each hallmark and summarize the available scientific evidence for targeting these mechanisms in dogs, primarily through nutrition. The framework is educational, not promotional, providing objective scientific information and noting gaps in scientific knowledge regarding geroprotection in companion animals.

The framework also connects the science of geroscience to real-world veterinary clinical practice and points out common misconceptions about aging in dogs. Importantly, the framework details situations when veterinary evaluation and treatment are needed, beyond geroprotective strategies. — Dr. JoAnna Pendergrass, DVM

Aging is the single largest risk factor for chronic disease in dogs. It is not one process but the convergence of several — interconnected, mutually reinforcing, and individually measurable — that progressively compromise organ reserve, functional capacity, and quality of life.

Geroscience is the discipline that studies these convergent processes: the biological mechanisms that link aging itself to the diseases and functional declines that accumulate in later life. In canine medicine, geroscience is accelerating — driven by the Dog Aging Project (the largest longitudinal companion-animal study ever conducted), canine rapamycin trials, epigenetic aging clocks, and growing recognition that the biology of aging in dogs is not merely analogous to human aging but often mechanistically conserved.

This page documents the six core control systems of mammalian aging as they operate in dogs. For each system, we present the biological mechanism, the available evidence (graded explicitly), the clinical translation for veterinary practice, the nutritional inputs that support normal function, and the boundaries where nutrition ends and medical intervention begins.

What this document is: A reference-grade scientific framework — written for veterinary professionals, formulation scientists, and informed dog owners who want to evaluate aging-biology claims against evidence.

What this document is not: A product brochure. Hollywood Elixir and Pet Gala are product lines aligned to LPL-01 pillars; they are mentioned where relevant to formulation architecture, not as promotional claims.

Regulatory note: All supplement-related statements describe support for normal biological structure and function. No disease-treatment, prevention, or cure claims are made or implied. Aging itself is a biological process, not a disease — the geroscience framework targets the mechanisms of aging, not specific disease endpoints.

How We Interpret Evidence

All mechanistic and ingredient-class claims in this document carry an evidence grade. We apply these conservatively and distinguish canine-specific from translational evidence.

Grade	Definition	Strength
A	Controlled canine randomized trial (RCT) or definitive canine interventional study, published in peer-reviewed veterinary or biomedical journals. Direct species-specific evidence.	Strongest. Direct causal inference in dogs.
B	Longitudinal canine cohort data, large observational studies (e.g., Dog Aging Project analyses), or well-designed non-randomized interventional studies in dogs.	Strong. Demonstrates association or real-world patterns, but confounders limit causal inference.
C	Rodent interventional data (lifespan studies, mechanistic knockout/overexpression models) with strong biological plausibility for translation to dogs.	Moderate. Mammalian aging biology is conserved, but dose, duration, and species-specific metabolism may differ substantially.
D	Mechanistic plausibility — in-vitro data, pathway-level evidence, human clinical data, or theoretical framework supported by first-principles biology. Not yet tested in dogs or rodent lifespan models.	Preliminary. Hypothesis-grade. Should not be presented as confirmed canine science.

What "translational evidence" means in geroscience: Many aging-biology findings originate in yeast, worms, flies, or mice and are subsequently validated in longer-lived mammals. A finding graded [C] or [D] is not unreliable — it is incomplete. The mammalian conservation of core aging pathways (mTOR, AMPK, sirtuins, NF-κB, telomere biology) provides a strong theoretical scaffold, but species-specific differences in metabolism, lifespan kinetics, and drug/nutrient handling mean that translation is never automatic.

How to read the grades: A claim tagged [A] can be stated with confidence. [B] is well-supported but not definitively causal. [C] is reasonable to hypothesize and worth investigating. [D] is scientifically grounded but awaits direct canine confirmation. We do not present [D]-grade evidence as fact.

The Six Control Systems of Canine Aging

Geroscience identifies several "hallmarks" or "pillars" of aging (López-Otín et al., 2013, revised 2023). For the purpose of canine translation, we organize these into six operationally distinct control systems — each measurable, each nutritionally addressable to some degree, and each with clear limits where veterinary medicine must take over.

Nutrient-Sensing & Metabolic Regulation (mTOR, AMPK, insulin/IGF-1, sirtuins)
Inflammatory Tone & Immune Aging (inflammaging, immunosenescence, NF-κB)
Oxidative Stress & Cellular Defense (ROS, Nrf2, mitochondrial quality)
Cellular Senescence & Tissue Renewal (senescent cell accumulation, SASP, stem-cell exhaustion)
Genomic & Epigenetic Integrity (DNA repair, methylation drift, telomere attrition)
Organ-System Reserve & Functional Capacity (renal, hepatic, cardiac, cognitive, musculoskeletal)

These are not independent silos. They interact continuously — inflammatory tone affects nutrient sensing, oxidative stress accelerates senescence, metabolic dysregulation erodes organ reserve. The framework is a map, not a set of isolated targets.

Figure: LPL-01 Canine Geroscience Control Systems Map — causal hierarchy and feedback architecture across six aging control systems.

Hierarchy: Primary vs. Secondary Drivers in Dogs

Not all six systems carry equal weight as intervention targets. Based on current canine evidence, we distinguish primary drivers (high-leverage, upstream systems where intervention has the broadest downstream effects) from secondary drivers (important but more often consequences of upstream dysregulation).

Primary Drivers (Highest Leverage)	Rationale
Nutrient-sensing & metabolic regulation	The mTOR/AMPK axis is the most-studied geroscience target in dogs. The Kealy caloric-restriction study [A] and the Dog Aging Project's rapamycin trial [A] both target this system. Metabolic health is the upstream master regulator — body condition is the single most actionable longevity lever.
Inflammatory tone & immune aging	Inflammaging is the dominant shared mechanism linking aging to nearly every canine age-related disease: arthritis, cognitive decline, cardiac disease, renal dysfunction, periodontal disease. It is also the most nutritionally addressable system (omega-3 evidence is Grade A).

Secondary Drivers (Important, Downstream)	Rationale
Oxidative stress & cellular defense	Real and measurable, but increasingly understood as a consequence of upstream metabolic and inflammatory dysregulation rather than a primary cause. Antioxidant-only strategies have limited lifespan effects in rodent models. [C/D]
Cellular senescence & tissue renewal	Emerging target with high theoretical importance. Senolytic research is pre-clinical in companion animals. No validated canine protocols exist. [C/D]
Genomic & epigenetic integrity	Measurable (canine DNA methylation clocks exist [B]) but not yet nutritionally addressable in a meaningful interventional sense. A monitoring tool, not yet an intervention target.
Organ-system reserve	The integrated output of all other systems. Not a "target" per se but the outcome measure that matters most clinically — and where the owner actually sees the impact of aging.

Multi-Pathway Architecture Statement

Why the LPL-01 formulation targets multiple aging control systems simultaneously:

The six control systems of canine aging are not independent — they interact through shared molecular machinery, common upstream regulators, and bidirectional feedback loops. A formulation that targets only one system ignores the cascade architecture of aging biology.

Key cross-system interactions:

Metabolic dysregulation → Inflammaging: Chronic mTOR activation (from obesity and caloric excess) directly upregulates NF-κB inflammatory signaling. Insulin resistance promotes pro-inflammatory adipokine secretion. You cannot address inflammaging without addressing metabolic health. [A/B]
Inflammaging → Oxidative stress: Chronic inflammatory activation generates ROS as a byproduct of immune-cell activity. NF-κB-driven inflammation and mitochondrial ROS production form a self-amplifying loop. [C]
Oxidative stress → Senescence: Persistent oxidative DNA damage is a primary trigger for cellular senescence. Senescent cells then produce SASP factors that drive further inflammation — creating a feed-forward loop between oxidative stress, senescence, and inflammaging. [C/D]
All upstream systems → Organ-system reserve: Organ reserve depletion is the integrated downstream consequence of all five preceding systems. Renal function, cognitive capacity, cardiac output, joint integrity, and muscle mass all decline as the cumulative burden of metabolic dysregulation, inflammation, oxidative damage, senescence, and genomic instability accumulates.

Formulation implication: The LPL-01 architecture addresses the two primary drivers (nutrient-sensing/metabolic regulation and inflammatory tone) with the strongest evidence-backed inputs (caloric moderation support, omega-3 EPA/DHA), while simultaneously providing substrate support for the secondary systems (antioxidant defense cofactors, methyl donors, organ-specific nutritional inputs). This multi-pathway approach reflects the biology: aging is a system-level phenomenon, not a single-target problem.

Formulation Architecture Mapping

How LPL-01 maps to the Six Control Systems of Canine Aging:

Attribution key: HE = Hollywood Elixir; PG = Pet Gala. Entries marked ⊘ are scientifically significant ingredients that are NOT included in the current LPL-01 formulation. They are documented here as comparative geroscience context and evidence anchors for their ingredient class — they do not appear in the formulation and should not be presented as LPL-01 actives.

Control System	LPL-01 Actives (HE / PG)	Mechanism	Evidence Grade	⊘ Significant Non-LPL-01 Context
1. Nutrient-sensing & metabolic regulation	HE: NR 60 mg (NAD⁺/sirtuin axis — SIRT1/SIRT3 substrate; the primary metabolic regulation anchor), Niacin/B3 2 mg (Preiss-Handler NAD⁺ biosynthesis), Resveratrol 15 mg (SIRT1 allosteric modulation; mild AMPK activation [C/D]), Quercetin 25 mg (AMPK activation in cell models [C/D]) PG: EPA/DHA from Omega 3-6-9 blend (insulin sensitivity support; improves cellular glucose uptake [A/B]), L-Carnitine 20 mg (long-chain fatty acid beta-oxidation → increased AMP:ATP ratio → indirect AMPK activation [B/C])	NR is the rate-limiting NAD⁺ substrate for SIRT1/SIRT3 deacetylation activity; canine NAD⁺ decline with age mirrors the human trajectory. EPA/DHA supports insulin sensitivity — the only sirtuin-adjacent metabolic input with Grade [A/B] canine evidence. L-Carnitine provides the mitochondrial fatty acid transport that constrains beta-oxidation flux in aging myocardium and skeletal muscle. Polyphenols offer mild, ancillary AMPK engagement	[A/B] (EPA/DHA insulin sensitivity) / [B/C] (L-Carnitine beta-oxidation/AMPK) / [C/D] (NR/sirtuin axis — strong mechanistic rationale; canine-specific aging data absent; human trials ongoing)	⊘ Fiber/prebiotics (glycemic modulation via microbiome-SCFA axis [B]) — not in LPL-01; ⊘ Spermidine (EP300-mediated autophagy induction, mTOR-independent [C/D]) — not in LPL-01; ⊘ Berberine (AMPK direct agonist, comparable to metformin in rodent models [C]) — not in LPL-01
2. Inflammatory tone & immune aging	HE: Quercetin 25 mg (NF-κB/IKK inhibition; NLRP3 inflammasome suppression; mast-cell mediator regulation [C/D]), Resveratrol 15 mg (NF-κB transcriptional modulation via SIRT1/p65 deacetylation [C/D]), Beta Glucans 50 mg (Dectin-1/TLR-4 innate immune training; promotes tolerogenic rather than hyperactivated baseline tone [A/B]), Reishi Mushroom 25 mg (beta-glucan/triterpenoid-mediated immune calibration; NK cell and macrophage regulation [B]), Vitamin E 15 IU (NF-κB gene suppression; membrane lipid peroxidation defense [B]), Astaxanthin 2 mg (NF-κB and COX-2 transcriptional attenuation [C]), Spirulina 50 mg (phycocyanin — anti-inflammatory; pro-resolving properties [C]), Blueberry/Anthocyanins 50 mg (COX-2 and NF-κB attenuation; NLRP3 suppression [C]) PG: EPA/DHA from Omega 3-6-9 150 mg (direct precursors for resolvins E1/D1/D2 and protectins D1/D3 — the specialized pro-resolving mediators that actively terminate inflammation [A]); Omega-7/Palmitoleic Acid 50 mg (anti-inflammatory adipokine modulation; NF-κB attenuation via PPAR-alpha [C])	EPA/DHA from Pet Gala holds the strongest canine evidence in this system — multiple Grade [A] RCTs demonstrating reduced inflammatory markers, improved clinical signs in atopic dermatitis and OA. Hollywood Elixir's polyphenol/mushroom/glucan stack addresses the transcriptional (NF-κB/NLRP3) and innate-immune-calibration arms — mechanisms complementary to, not duplicative of, the EPA/DHA resolvin axis. Beta-glucans are an underappreciated immune-training input with Grade [A/B] evidence for innate immune modulation	[A] (EPA/DHA resolvin precursors — multiple canine RCTs) / [A/B] (Beta Glucans innate immune training) / [B] (Vitamin E inflammatory gene modulation; Reishi immune calibration) / [C/D] (Quercetin NF-κB/NLRP3; Resveratrol NF-κB; Astaxanthin; Spirulina; Blueberry)	⊘ Curcumin (NF-κB/IKK inhibition; two canine OA RCTs with phytosomal forms [C/D]) — not in LPL-01; ⊘ Boswellia serrata (5-LOX inhibition via boswellic acids; some positive canine OA data [C]) — not in LPL-01; ⊘ Prebiotics/fermentable fiber (SCFA production → gut-immune tone; gut barrier integrity [B]) — not in LPL-01
3. Oxidative stress & cellular defense	HE: Glutathione 50 mg (direct intracellular GSH supply — the master intracellular antioxidant; defends against lipid peroxidation, protein oxidation, and mitochondrial ROS; canine oral bioavailability of reduced glutathione is subject to PK2/PK3 uncertainty but liposomal/reduced forms show improving evidence [C/D]), Vitamin C 10 mg (aqueous-phase scavenger; directly regenerates oxidized Vitamin E; GSH recycling via dehydroascorbate reductase; prolyl hydroxylase cofactor for collagen cross-linking [B]), Vitamin E 15 IU (lipid-phase tocopherol — primary membrane peroxidation defense; terminates lipid radical chain reactions [B]), Astaxanthin 2 mg (membrane-spanning carotenoid that uniquely crosses both the blood-brain and blood-retinal barriers, providing CNS antioxidant coverage that tocopherol cannot match [C]), CoQ10 40 mg (Complex I–II bridge in the mitochondrial electron transport chain; reduces electron leak and mitochondrial ROS generation at source [C]) PG: Zinc 1.5 mg chelated (structural cofactor for Cu/Zn-SOD — cytosolic superoxide dismutase isoform; also required for catalase activity; chelated form bypasses phytate interference [B])	Multi-compartment ROS defense is the structural principle: lipid phase (Vitamin E), aqueous phase (Vitamin C + Glutathione), membrane-spanning/CNS coverage (Astaxanthin), mitochondrial ROS source attenuation (CoQ10), and enzymatic antioxidant arm (Zinc/SOD). Glutathione's direct supplementation distinguishes this formulation from NAC-dependent approaches that require de novo synthesis — a meaningful distinction in aging dogs where cysteine supply is rate-limiting	[B] (Vitamin E lipid antioxidant; Zinc SOD cofactor; CoQ10 mitochondrial ETC) / [C] (Astaxanthin BBB penetration; Vitamin C multi-pathway) / [C/D] (Glutathione oral bioavailability in dogs — mechanism is correct; delivery to intracellular pools is the open question)	⊘ Selenium (essential GPx enzyme family cofactor — not in LPL-01; GPx is the primary enzymatic defense against lipid hydroperoxides [B]); ⊘ NAC (N-acetylcysteine — rate-limiting cysteine donor for glutathione synthesis; veterinary use well-established for acetaminophen toxicity [C/D] — not in LPL-01); ⊘ Sulforaphane (isothiocyanate Nrf2 activator — induces endogenous antioxidant enzyme production via KEAP1 inhibition [C/D] — not in LPL-01); ⊘ Copper/Manganese (metalloenzyme cofactors for Cu/Zn-SOD and Mn-SOD respectively [B] — not in LPL-01)
4. Cellular senescence & tissue renewal	HE: Quercetin 25 mg (modest senolytic activity via BCL-2/BCL-XL inhibition; p16INK4a+ cell reduction in rodent models [D — no canine data]; note that this mechanism requires significantly higher doses than anti-inflammatory applications — the 25 mg dose is better characterized as anti-inflammatory than senolytic), NR 60 mg (NAD⁺/SIRT6 axis attenuates SASP cytokine production in senescent cells; NR prevents DNA-damage-induced senescence entry by supporting PARP-1-mediated repair [C/D]), Resveratrol 15 mg (SIRT1-mediated p21/p53 pathway modulation; SASP attenuation; anti-senescence transcriptional regulation [C/D]), Spirulina 50 mg + Blueberry 50 mg (antioxidant burden reduction limits oxidative-stress-driven senescence entry — a quantitatively significant upstream lever [C])	Canine senolytic science is at Grade [D] — no species-specific data exists for any nutraceutical. The formulation addresses this system primarily through upstream mechanisms: NR reduces the DNA damage that triggers senescence entry; the antioxidant stack reduces oxidative senescence induction; SIRT1/SIRT6 activation attenuates SASP amplitude in cells that are already senescent. Direct senolytic clearance (removing p16+ cells) is not achievable by any component of the current formulation at maintenance doses. This is an honest constraint, not a gap in formulation design	[D] (Quercetin senolytic — rodent models only; no canine efficacy data; daily 25 mg dose sub-therapeutic for senolytic vs. anti-inflammatory applications) / [C/D] (NR/SIRT6 SASP attenuation; Resveratrol SIRT1/p53) / [C] (antioxidant stack — oxidative senescence-entry reduction)	⊘ Fisetin (most potent flavonoid senolytic in systematic comparison; 25–50% p16INK4a/p21+ clearance in rodent models; Grade [D] — no canine efficacy, safety, or PK data — not in LPL-01); ⊘ Spermidine (EP300 acetyltransferase inhibition → autophagy induction; mTOR-independent mechanism; lifespan extension in multiple model organisms [C/D] — not in LPL-01); ⊘ Dasatinib + Quercetin (best-studied senolytic combination in rodents; Dasatinib is a prescription tyrosine-kinase inhibitor, not nutraceutical-appropriate)
5. Genomic & epigenetic integrity	HE: NR 60 mg (NAD⁺ elevation activates SIRT6 — the genomic stability sirtuin; SIRT6 directly recruits and activates PARP-1 at DNA double-strand break sites; NR also supports PARP-1's NAD⁺-dependent ADP-ribosylation of DNA repair proteins [C/D]), B-vitamins — B12 0.25 mg, B6 1 mg, Niacin/B3 2 mg (one-carbon metabolic cycle: B12 as methyl-cobalamin donor; B6 as PLP cofactor in transsulfuration and methylation; niacin contributes to methyl-donor pool balance; folate-equivalent one-carbon flux supports DNMT activity and maintenance methylation [C/D]), Resveratrol 15 mg (SIRT1 deacetylase activity on histone H3K9/H4K16 — epigenetic maintenance [C/D]), Quercetin 25 mg (NRF2-pathway epigenetic modulation; Dnmt3a/b regulation in cancer cell models [D]) PG: Zinc 1.5 mg chelated (structural cofactor for three zinc-finger DNA repair proteins: OGG1 — the 8-oxoguanine glycosylase that excises oxidative DNA lesions; PARP-1 — the DNA nick-sensing and repair initiation enzyme; p53 — the guardian of genomic integrity. Chelated form ensures bioavailability is not compromised by phytate competition [B])	NR→NAD⁺→SIRT6/PARP-1 is the most direct genomic maintenance mechanism in the formulation — and the one with the strongest biochemical rationale. B-vitamins maintain the one-carbon cycle that sustains epigenetic methylation patterns — the most widely studied nutritional epigenomic intervention. Zinc provides cofactor availability for the three key zinc-finger DNA repair proteins simultaneously. All mechanisms are plausible and biochemically well-characterized; canine-specific aging intervention trials for NAD⁺ precursors and epigenetic substrates remain absent from the literature	[B] (Zinc — DNA repair enzyme cofactor) / [C/D] (NR/NAD⁺/SIRT6 — strong mechanistic rationale; no direct canine aging-intervention data; human clinical trials ongoing) / [C/D] (B-vitamins methylation cycle in aging dogs)	⊘ SAMe (S-adenosylmethionine — the direct substrate for DNA methyltransferases; also glutathione precursor via transsulfuration — not in LPL-01; established veterinary hepatoprotection and cognitive support application [B/C]); ⊘ Spermidine (EP300 histone acetyltransferase inhibition → global histone hypoacetylation pattern associated with longevity in model organisms [C/D] — not in LPL-01)
6. Organ-system reserve & functional capacity	HE: CoQ10 40 mg (cardiac: mitochondrial ETC efficiency in cardiomyocytes; CoQ10 plasma levels decline significantly in aging dogs and in DMVD [C]; general: mitochondrial energy supply across all high-demand organ systems), B-vitamins/B12/B6/Niacin (neuronal: one-carbon metabolic support for neuronal maintenance; cognitive protection [B/C]), NR 60 mg (broad organ reserve: systemic cellular NAD⁺ support for metabolically demanding tissues [C/D]), Blueberry/Anthocyanins 50 mg (cognitive: BDNF upregulation; neuronal oxidative protection; modest cognitive outcomes in aged beagle model [C]), Whey Protein Isolate 250 mg (musculoskeletal: leucine-rich BCAA supply for mTORC1-dependent muscle protein synthesis; sarcopenia prevention substrate [B]) PG: EPA/DHA 150 mg blend (joint: Grade [A] by 72-trial meta-analysis — omega-3 is the strongest single nutraceutical for canine OA; cardiac: cardioprotective anti-inflammatory; renal: anti-inflammatory, phospholipid support; cognitive DHA: neuronal membrane composition [A–B]), L-Carnitine 20 mg (cardiac: ~60% of myocardial energy derived from LCFA beta-oxidation; carnitine deficiency established as a cause of reversible DCM in susceptible breeds [A]; skeletal muscle: mitochondrial energy substrate [B/C]), Marine Collagen Peptides 500 mg + Hydrolyzed Whey 250 mg + Beef Gelatin 200 mg + Bone Broth 100 mg + Hyaluronic Acid 50 mg + MSM 100 mg (joint/connective tissue: structural matrix substrate supply providing pre-formed proline/hydroxyproline/glycine, GAG hydration via HA, bioavailable sulfur via MSM [B]), Omega-7/Palmitoleic Acid 50 mg (epithelial and mucosal tissue maintenance; anti-inflammatory adipokine modulation [C]), Zinc 1.5 mg (multi-organ enzymatic cofactor), Ceramides 8 mg (epithelial barrier [C])	EPA/DHA is the evidence backbone of System 6 — the only ingredient with Grade [A] evidence for joint function and meaningful Grade [B] evidence across cardiac, renal, and cognitive domains simultaneously. L-Carnitine addresses the cardiac beta-oxidation substrate deficit that underlies DCM pathophysiology in carnitine-deficient dogs. The collagen/HA/MSM structural stack from Pet Gala fills the ECM maintenance gap that Hollywood Elixir intentionally does not address. CoQ10 and NR provide broad mitochondrial energy support for all organ systems	[A] (EPA/DHA joint and cardiac; L-Carnitine DCM-specific) / [B] (EPA/DHA renal, cognitive; CoQ10; Whey protein/sarcopenia; Collagen/HA/MSM structural) / [C] (Astaxanthin brain/retina; Blueberry cognitive; Omega-7; CoQ10 cardiac) / [C/D] (NR organ energy reserve)	⊘ MCTs C8/C10 (Grade [A] canine RCTs for CCD — 3 trials; ketone bodies as alternative brain fuel bypassing impaired glucose metabolism — clinically meaningful for a condition affecting 28–68% of dogs over age 11 — not in LPL-01; requires caloric contribution); ⊘ UC-II undenatured type II collagen (oral tolerance mechanism; 4 canine RCTs; non-inferior to NSAID in 76-dog trial — not in LPL-01); ⊘ Taurine standalone (Grade [A] for DCM in specific susceptible breeds; 7/12 dogs reversed DCM with taurine alone — not in LPL-01 as standalone supplement; whey protein provides taurine biosynthesis precursors but not equivalent to direct taurine supplementation in deficiency states); ⊘ SAMe (hepatoprotection: NF-κB inhibition in canine hepatocytes; GSH precursor; established veterinary hepatology application [B/C] — not in LPL-01); ⊘ Phosphatidylserine (brain membrane fluidity; cognitive support [B/C] — not in LPL-01)

How to read this table: Ingredients are listed with doses per sachet where product-specific. HE and PG provide complementary coverage — HE is designed around the NAD⁺/antioxidant/immune-calibration axis; PG is designed around the structural/lipid/ECM axis. Together they address all six systems. Systems 1–2 have the strongest evidence base; Systems 4–5 are addressed through upstream and indirect mechanisms due to the absence of canine-specific senolytic data. The ⊘ column preserves scientific completeness — these are real ingredients with real evidence; their absence from the formulation reflects scope decisions, not ignorance of the science.

What this table does not claim: The formulation does not claim to extend canine lifespan. It claims to supply nutritional substrates that support normal biological function across the six aging control systems. The distinction between healthspan support and lifespan extension is maintained throughout this document.

Measurable Operational Anchors: Canine Senior Screening Framework

Before addressing each control system in molecular terms, clinicians and owners need a shared vocabulary for measuring aging in observable, repeatable clinical metrics.

Domain	Metric / Tool	When to Start	Frequency
Body composition	Body Condition Score (BCS, 1–9 scale); Muscle Condition Score (MCS: normal, mild loss, moderate loss, severe loss)	All ages; formalized at age 7 (large/giant), age 9 (small/medium)	Every 6 months in seniors
Mobility & gait	Gait assessment (visual or force-plate); joint range of motion; owner mobility questionnaire (e.g., CBPI — Canine Brief Pain Inventory; LOAD — Liverpool Osteoarthritis in Dogs)	Age 7+ (breed-dependent; earlier for predisposed breeds)	Every 6–12 months
Cognitive function	Canine Cognitive Dysfunction Rating Scale (CCDR); DISHAAL checklist (Disorientation, Interaction changes, Sleep-wake disruption, House soiling, Activity changes, Anxiety, Learning/memory deficits)	Age 8–9+	Annually; more frequently if signs emerge
Renal function	SDMA, creatinine, BUN, UPC (urine protein:creatinine ratio), urine specific gravity → IRIS CKD staging if applicable	Age 7+ (earlier for predisposed breeds: Cavalier King Charles Spaniel, Bull Terrier, Cocker Spaniel)	Annually; biannually if IRIS Stage 1–2 detected
Cardiac screening	Auscultation, NT-proBNP (or cardiac troponin I), echocardiography for predisposed breeds	Breed-dependent (CKCS, Doberman, Boxer, Great Dane → earlier screening)	Per ACVIM breed-specific guidelines
Hepatic function	ALT, ALP, GGT, bile acids, albumin	Age 7+	Annually
Comprehensive bloodwork	CBC, chemistry panel, T4, urinalysis	Age 7+	Annually; biannually age 10+
Oral health	Full dental examination, periodontal staging	All ages	Annually; dental radiographs as indicated

These intervals represent a reasonable standard-of-care framework. Individual patients may require more frequent monitoring based on breed, existing conditions, or risk factors. Breed-size profoundly affects the definition of "senior": a Great Dane at 6 years is geriatrically equivalent to a Chihuahua at 11–12.

System 1: Nutrient-Sensing & Metabolic Regulation

The Biology

Four nutrient-sensing pathways form the metabolic "dashboard" of the aging cell:

mTOR (mechanistic Target of Rapamycin): A kinase complex that integrates signals from amino acids, growth factors, energy status, and oxygen levels to regulate cell growth, protein synthesis, and autophagy. When chronically activated (by persistent caloric excess or high amino-acid flux), mTOR suppresses autophagy — the cell's recycling and quality-control system — and accelerates age-related decline. [C — rodent lifespan data; A — canine rapamycin trial data from the Dog Aging Project]

AMPK (AMP-Activated Protein Kinase): The cellular energy sensor. Activated by low energy states (exercise, caloric restriction, fasting), AMPK promotes autophagy, mitochondrial biogenesis, and insulin sensitivity. It is functionally antagonistic to mTOR. In aged dogs, AMPK responsiveness declines. [C]

Insulin/IGF-1 signaling: Chronic hyperinsulinemia (from obesity, excess carbohydrate intake, or insulin resistance) suppresses autophagy, promotes lipogenesis, and accelerates cellular aging. Reduced IGF-1 signaling is one of the most conserved longevity-associated phenotypes across species, from worms to dogs. Small dogs (lower IGF-1, via the IGF1 gene variant) live longer than large dogs — this is one of the most robust associations in canine geroscience. [A/B — Dog Aging Project; Greer et al., 2007]

Sirtuins (SIRT1–7): NAD+-dependent deacetylases involved in DNA repair, metabolic regulation, and stress resistance. Sirtuin activity declines with age as NAD+ levels fall. Compounds like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) aim to restore NAD+ pools, but canine-specific data is limited. [C/D]

How This Manifests in Aging Dogs

Progressive insulin resistance, especially in overweight and obese dogs — and more than 50% of US dogs are overweight or obese [B]
Declining autophagy → accumulation of damaged organelles, misfolded proteins, and cellular debris
Reduced metabolic flexibility → less ability to switch between glucose and fatty-acid fuel sources
Sarcopenia (age-related muscle loss) accelerated by mTOR dysregulation and reduced protein-synthesis efficiency [B]
Breed-size effect: large/giant breeds age faster, with higher IGF-1 levels correlating to shorter lifespans across breeds [A/B]

Key Nutritional Inputs

Input	Mechanism	Evidence
Caloric moderation / lean body-mass maintenance	Reduces chronic mTOR activation; improves insulin sensitivity; the single most evidence-backed longevity intervention in dogs	[A] — Kealy et al., 2002: lean-fed Labradors lived a median 1.8 years longer than ad-libitum-fed littermates
Omega-3 (EPA/DHA)	Improves insulin sensitivity; modulates mTOR signaling in some tissues	[A/B]
Polyphenols (e.g., quercetin, EGCG)	AMPK activation, mild mTOR modulation in cell and rodent models	[C/D]
Fiber / low-glycemic carbohydrate profile	Reduces postprandial insulin spikes; supports metabolic flexibility	[B]
NMN / NR (NAD+ precursors)	Theoretical sirtuin support via NAD+ repletion; human trials ongoing; canine data limited	[D]

Practical Translation (Editorial)

Body condition is the most actionable geroscience lever. Maintaining a BCS of 4–5/9 throughout life is the closest thing to a proven longevity intervention in dogs. The Kealy et al. (2002) study remains the strongest single piece of canine aging data. [A]
Metabolic screening at the senior visit: Fasting glucose, fructosamine, insulin (where available), and lipid panel provide a metabolic snapshot. Trends over serial visits are more informative than single values.
Breed-size context matters profoundly. A 10-year-old Chihuahua and a 7-year-old Great Dane are both "senior," but their metabolic aging trajectories, IGF-1 profiles, and intervention windows differ substantially. Geroscience recommendations should be breed-size adjusted.
Obesity is not a cosmetic issue. It is a state of chronic mTOR activation, insulin resistance, and systemic low-grade inflammation. In geroscience terms, obesity accelerates every aging pathway simultaneously.
Time-restricted feeding (once-daily feeding) is increasingly studied. The Dog Aging Project has reported associations between once-daily feeding and improved health metrics across multiple domains. [B] This does not mean prolonged fasting is safe — it means meal-timing deserves veterinary conversation.

Common Owner Misinterpretations

"My dog is just a little chunky — it's fine." Excess body condition is not benign. Every unit above BCS 5/9 is associated with increased inflammatory markers, reduced insulin sensitivity, and epidemiologically with reduced lifespan. The Kealy study quantified this: 1.8 years of life, from body condition alone. [A]

"Old dogs are supposed to slow down." Reduced activity in senior dogs should be investigated, not accepted. It may reflect pain (osteoarthritis affects >60% of dogs over 7), metabolic dysfunction, cognitive decline, or cardiac disease — all of which have management options.

"Fasting is dangerous for dogs." Time-restricted feeding within veterinary guidance is a legitimate AMPK-activating, autophagy-promoting strategy. This does not mean skipping meals arbitrarily; it means that meal timing and frequency are geroscience-relevant variables worth discussing with a veterinarian. [B]

Where Geroscience Does NOT Replace Diagnosis

Diabetes mellitus (Type I or II) requires medical management — insulin therapy, dietary prescription, and glucose monitoring. Nutritional geroscience supports metabolic health; it does not treat diabetes.
Hyperadrenocorticism (Cushing's disease) mimics metabolic aging (muscle wasting, skin changes, insulin resistance) but requires endocrine diagnosis and specific treatment.
Hypothyroidism affects metabolic rate and body composition; it requires thyroid hormone supplementation, not just nutritional optimization.
Insulinoma and other metabolic neoplasia require oncologic intervention.

System 2: Inflammatory Tone & Immune Aging

The Biology

Inflammaging — the progressive, sterile, low-grade chronic inflammation that develops with age — is now considered the dominant shared mechanism linking biological aging to virtually every age-related disease in mammals (Franceschi et al., 2000; 2018). [C — mechanistic framework established in humans/rodents; B — canine observational data supporting the phenomenon]

The key molecular machinery:

NF-κB: The master transcription factor for inflammatory gene expression. NF-κB activity increases with age across all tissues studied. It drives production of IL-1β, IL-6, TNF-α, and other pro-inflammatory mediators that, when chronically elevated, damage tissues throughout the body.
NLRP3 inflammasome: An intracellular danger sensor that, when activated, cleaves pro-IL-1β into active IL-1β and can trigger pyroptotic cell death. NLRP3 becomes chronically overactive with age, contributing to sterile inflammation.
Immunosenescence: The progressive decline of adaptive immune function — reduced naïve T-cell production, thymic involution, impaired vaccine responses — paired with compensatory innate immune overactivation. The immune system becomes simultaneously less effective and more inflammatory.
Resolvin/protectin/maresin pathways: EPA- and DHA-derived specialized pro-resolving mediators (SPMs) that actively terminate inflammation and promote tissue repair. These resolution pathways decline with age, meaning inflammation initiates normally but fails to resolve properly — it becomes self-perpetuating.

How This Manifests in Aging Dogs

Chronic low-grade inflammation detectable on bloodwork (elevated CRP, IL-6) even in clinically "healthy" senior dogs [B]
Increased susceptibility to infection alongside paradoxical immune overreactivity (allergies, autoimmune tendencies) — the hallmark dual failure of immunosenescence
Periodontal disease as both a consequence and a driver of systemic inflammaging — the oral-systemic inflammation axis [B]
Chronic osteoarthritis pain driven by inflammatory mediators (IL-1, TNF-α, PGE2) in synovial tissue
Neuroinflammation contributing to cognitive decline and canine cognitive dysfunction (CCD) [B]
Impaired wound healing and tissue repair capacity
Reduced vaccine efficacy in senior dogs — immune responses to vaccination diminish with age

Key Nutritional Inputs

Input	Mechanism	Evidence
EPA / DHA (marine omega-3s)	Substrate for resolvins, protectins, maresins — the resolution arm of inflammation. Directly competes with arachidonic acid for cyclooxygenase and lipoxygenase pathways.	[A] — Multiple canine trials: reduced inflammatory markers, improved clinical signs in atopic dermatitis, osteoarthritis, renal disease
Curcumin (bioavailable forms)	NF-κB pathway modulation; COX-2 inhibition; antioxidant	[C/D] — Rodent and human data strong; canine-specific bioavailability and efficacy data limited
Quercetin	Mast-cell stabilization; NF-κB modulation; NLRP3 inflammasome inhibition (in-vitro)	[C/D]
Vitamin E (mixed tocopherols)	Membrane antioxidant; modulates inflammatory gene expression at the transcriptional level	[B]
Boswellia serrata	5-LOX inhibition via boswellic acids; anti-inflammatory resin	[C] — Some positive canine OA studies exist, but methodological quality varies
Prebiotics / fermentable fiber	Supports gut microbiome composition and short-chain fatty acid (SCFA) production → influences systemic immune tone and intestinal barrier integrity	[B] — Canine microbiome and SCFA studies

Practical Translation (Editorial)

Inflammaging is subclinical before it is clinical. Low-grade chronic inflammation doesn't present with an obvious chief complaint. It manifests as gradual, multi-system functional decline. Serial CRP or species-specific inflammatory marker tracking (where available) can provide objective longitudinal data.
Periodontal disease is the most common — and most undertreated — source of chronic inflammation in dogs. Annual professional dental assessment and appropriate intervention are arguably the highest-ROI anti-inflammaging strategy available in routine clinical practice. [B]
Omega-3 supplementation has the strongest evidence base of any anti-inflammatory nutritional intervention in dogs. Therapeutic doses for meaningful inflammatory modulation (EPA+DHA combined: roughly 50–100 mg/kg/day, adjusted to patient) are well above what most commercial diets provide. [A]
Chronic NSAID or corticosteroid use addresses symptoms of inflammaging but does not resolve the underlying biology — and carries well-documented long-term risks (GI, renal, hepatic). Nutritional anti-inflammatory support can complement (not replace) pharmacologic management as part of a multimodal strategy.

Common Owner Misinterpretations

"Inflammation is always bad." Acute inflammation is a vital defense mechanism — it fights infection, clears damaged tissue, and initiates repair. The problem is not inflammation itself but the failure to resolve inflammation, leading to chronic, purposeless, tissue-damaging activation. Geroscience targets the resolution failure, not inflammation per se.

"My dog doesn't seem inflamed — no redness or swelling." Inflammaging is systemic and often invisible. The affected dog appears "normal" but is functioning at reduced capacity across multiple organ systems. It is a biochemical state detectable on bloodwork, not a visible lesion.

"Anti-inflammatory supplements replace anti-inflammatory drugs." They do not. Nutritional inputs support the resolution side of inflammation (pro-resolving mediators, antioxidant defense). They do not provide the acute analgesic or immunosuppressive effects of NSAIDs or corticosteroids. Both have a role; neither replaces the other.

Where Geroscience Does NOT Replace Diagnosis

Immune-mediated diseases (IMHA, ITP, immune-mediated polyarthritis, pemphigus) require immunosuppressive therapy under specialist supervision.
Sepsis and systemic infection require antimicrobial and intensive supportive medical intervention.
Neoplasia-associated inflammation requires oncologic treatment of the underlying malignancy.
Acute pancreatitis requires hospitalization, fluid therapy, and aggressive pain management.
Inflammatory bowel disease (IBD) often requires immunosuppressive drug therapy alongside dietary management; histopathologic confirmation is essential to differentiate from alimentary lymphoma.

System 3: Oxidative Stress & Cellular Defense

The Biology

Reactive oxygen species (ROS) are inevitable byproducts of mitochondrial respiration. In moderation, ROS serve as essential signaling molecules — a phenomenon called hormesis. In excess, or when antioxidant defense systems are overwhelmed, ROS damage lipids, proteins, and DNA, accelerating cellular aging. [C/D — mechanistic framework]

The cellular defense architecture:

Nrf2 pathway: The master regulator of antioxidant gene expression. When activated by mild oxidative stress, Nrf2 translocates to the nucleus and upregulates genes for glutathione synthesis, superoxide dismutase, catalase, heme oxygenase-1, and other protective enzymes. Nrf2 responsiveness declines with age. [C]
Glutathione (GSH): The most abundant intracellular antioxidant. GSH levels decline significantly with age across tissues. Maintaining GSH synthesis capacity — via cysteine precursors (NAC), glycine, and the cofactor selenium — is a primary nutritional strategy.
Mitochondrial quality control (mitophagy): Selective autophagy of damaged, ROS-generating mitochondria prevents their accumulation. This process declines with age and intersects directly with mTOR/AMPK signaling — connecting oxidative defense back to metabolic regulation.
Enzymatic antioxidants (SOD, catalase, glutathione peroxidase): These require mineral cofactors — zinc, copper, and manganese for SOD isoforms; selenium for glutathione peroxidase; iron for catalase.

Important Reframing: Oxidative Stress as Consequence, Not Primary Cause

The "free radical theory of aging" (Harman, 1956) has been substantially revised over the past two decades. High-dose, single-antioxidant supplementation trials (vitamin E, vitamin C, beta-carotene) have largely failed to extend lifespan in rodent models — and some have shown harm. [C]

Current understanding: oxidative stress is more often a downstream consequence of metabolic dysregulation and chronic inflammation than an independent primary driver of aging. This reframing has direct implications for formulation design and owner expectations. The most effective oxidative-defense strategies are:

Supporting endogenous antioxidant systems (Nrf2 activation, glutathione synthesis) rather than flooding the system with exogenous antioxidants
Addressing upstream metabolic and inflammatory drivers — the root causes of excess ROS production
Maintaining mitochondrial quality control through exercise, caloric moderation, and autophagy support

Key Nutritional Inputs

Input	Mechanism	Evidence
Selenium	Essential cofactor for glutathione peroxidase (GPx) family — the primary enzymatic defense against lipid peroxidation	[B]
Zinc, Copper, Manganese	Cofactors for cytosolic Cu/Zn-SOD, mitochondrial Mn-SOD — front-line superoxide dismutation	[B]
Vitamin E (mixed tocopherols)	Lipid-phase chain-breaking antioxidant; protects cell membranes from peroxidation	[B]
Vitamin C (ascorbic acid)	Water-phase antioxidant; regenerates oxidized vitamin E; collagen synthesis cofactor	[B] — Dogs synthesize vitamin C endogenously; supplementation may benefit stressed, ill, or aging dogs where demand exceeds synthesis
NAC (N-acetylcysteine)	Rate-limiting cysteine donor for glutathione synthesis	[C/D] — Veterinary use established for acetaminophen toxicity; chronic oral supplementation data in dogs is limited
Astaxanthin	Potent lipid-soluble antioxidant; uniquely crosses blood-brain and blood-retinal barriers	[C]
Sulforaphane (broccoli seed extract)	Nrf2 activator → upregulates endogenous antioxidant enzyme production rather than acting as a direct scavenger	[C/D]

Practical Translation (Editorial)

Don't chase antioxidant supplements — chase the upstream problem. An obese, sedentary, chronically inflamed dog on a high-antioxidant supplement is still aging rapidly. Address metabolic health and inflammaging first; antioxidant support is adjunctive, not primary.
Exercise is the most potent Nrf2 activator available. Appropriate, consistent physical activity triggers hormetic oxidative stress that upregulates the body's own antioxidant defenses. Prescribing exercise is prescribing geroscience — and it costs nothing.
Oxidative-stress biomarkers are emerging. Serum 8-OHdG (DNA oxidation), malondialdehyde (lipid peroxidation), and glutathione levels are available in research settings and increasingly in commercial panels. These may become routine senior screening tools.

Common Owner Misinterpretations

"More antioxidants = better." Excess exogenous antioxidants can suppress the body's own adaptive defense systems (the hormetic response). High-dose vitamin E supplementation in some human trials was associated with increased mortality. Balance and endogenous system support matter more than maximizing intake.

"My dog needs an antioxidant supplement because he's old." Possibly — but only as part of a comprehensive strategy. An antioxidant supplement will not compensate for obesity, sedentary lifestyle, untreated dental disease, or unmanaged chronic inflammatory conditions.

Where Geroscience Does NOT Replace Diagnosis

Acute oxidative emergencies (toxin ingestion, reperfusion injury, heat stroke) require immediate emergency medical management.
Hepatic disease (where oxidative stress is a major pathologic component) requires veterinary diagnosis and targeted treatment — not antioxidant supplementation alone.
Cataracts and retinal degeneration require ophthalmologic assessment and, where available, surgical intervention.
Hemolytic anemia from oxidant exposure (onion/garlic, zinc toxicosis, acetaminophen in rare cases) requires emergency stabilization.

System 4: Cellular Senescence & Tissue Renewal

The Biology

Cellular senescence is a state of permanent cell-cycle arrest. Senescent cells stop dividing but do not die. Instead, they accumulate in tissues with age and secrete a complex mixture of pro-inflammatory cytokines, matrix-degrading proteases, and growth factors collectively termed the SASP (Senescence-Associated Secretory Phenotype). [C/D]

The SASP makes senescence directly relevant to inflammaging and tissue degradation:

Senescent cells recruit immune cells, creating local inflammatory microenvironments
They degrade extracellular matrix via secreted matrix metalloproteinases (MMPs)
They impair neighboring stem-cell function, reducing tissue renewal capacity
They promote fibrosis in affected organs — kidney, liver, lung, joint capsule

In rodent models, genetic or pharmacologic clearance of senescent cells extends healthspan and, in some studies, lifespan. [C]

Stem-cell exhaustion — the progressive decline of tissue-resident stem-cell populations — compounds the problem. Tissues lose their capacity for self-renewal, contributing to sarcopenia, impaired wound healing, thinning skin, and declining organ function.

Status in Dogs

This is the least mature of the six control systems in terms of canine-specific evidence:

Senescent cell burden has been measured in canine tissues in limited studies [C/D]
No senolytic drugs are approved or standardized for veterinary use in dogs
Fisetin (a plant flavonoid from strawberries) is the most-discussed nutraceutical senolytic, with rodent data showing senescent-cell clearance — but canine pharmacokinetics, dosing, and safety data are essentially absent [D]
Quercetin + dasatinib is the best-studied senolytic combination in rodent models; however, dasatinib is a prescription tyrosine-kinase inhibitor (a cancer drug) and is not appropriate for nutraceutical use [C — rodent only]
The Dog Aging Project is investigating senescence-related biomarkers, which may eventually enable clinical monitoring [B — in progress]

Key Nutritional Inputs (Speculative — Predominantly Grade D)

Input	Proposed Mechanism	Evidence
Fisetin	Senolytic activity demonstrated in rodent models (clearance of p16INK4a-positive cells)	[D] — No canine efficacy or safety data
Quercetin	Modest senolytic properties in rodent models; better-established as anti-inflammatory and mast-cell stabilizer	[D] for senolytic; [C] for anti-inflammatory
Spermidine	Autophagy induction → may promote clearance of senescent cells and damaged organelles	[C/D] — Rodent lifespan data exists; no canine data

Practical Translation (Editorial)

Senolytics are exciting science but premature as clinical recommendations for dogs. No veterinary senolytic protocol exists. Fisetin and quercetin are available over the counter, but they have not been validated for senolytic effect in dogs. Owners purchasing "senolytic" supplements are buying rodent-stage science.
The practical veterinary proxy for senescence is tissue function. Clinicians assess the downstream consequences of senescent cell accumulation by monitoring organ reserve (renal, hepatic, cardiac function), tissue quality (skin elasticity, wound healing speed, muscle mass), and functional capacity (mobility, cognition).
Stem-cell therapies are marketed in veterinary medicine (primarily for osteoarthritis), but the evidence base is heterogeneous and quality control varies widely across providers. Regulatory frameworks are still evolving.

Common Owner Misinterpretations

"Fisetin reverses aging in dogs." There is no published evidence that fisetin extends lifespan or meaningfully clears senescent cells in dogs. Rodent data is promising and has generated legitimate scientific interest. Translation to companion animals requires canine-specific trials that have not yet been conducted.

"My dog needs stem-cell therapy to fight aging." Stem-cell therapy is a medical procedure with specific indications, variable evidence, significant cost, and no established role as a general aging intervention. It should only be pursued through licensed veterinary practitioners for defined orthopedic or other conditions.

Where Geroscience Does NOT Replace Diagnosis

Cancer is the ultimate failure of cell-cycle control. While senescence research provides important mechanistic insight, neoplasia requires oncologic management — surgery, chemotherapy, radiation, or immunotherapy.
Degenerative joint disease, organ fibrosis, and other end-stage tissue deterioration require medical and/or surgical management.

System 5: Genomic & Epigenetic Integrity

The Biology

The genome accumulates damage over a lifetime — from endogenous sources (ROS, replication errors, deamination) and exogenous sources (UV radiation, environmental toxins, mutagenic chemicals). Cells deploy elaborate repair machinery (base excision repair, nucleotide excision repair, homologous recombination, non-homologous end joining), but repair fidelity declines with age, and the balance tips toward accumulating unrepaired damage. [C/D]

Epigenetic drift — the progressive dysregulation of gene-expression patterns without changes to the DNA sequence itself — is now recognized as a core hallmark of aging. DNA methylation patterns change predictably with age, forming the basis of "epigenetic clocks" that can estimate biological age independently of chronological age.

Canine epigenetic clocks have been developed and validated by the Dog Aging Project and independent researchers (Thompson et al., 2017). These tools can estimate a dog's biological age from a DNA methylation profile obtained via blood or saliva sample. [B]

Telomere attrition — the progressive shortening of chromosome-protective end caps with each cell division — was among the first identified molecular markers of aging. Telomere length correlates with remaining replicative capacity. However, telomere-focused interventions (telomerase activation) carry theoretical cancer risk and are not viable nutritional targets. [D]

Key Nutritional Inputs

Input	Proposed Mechanism	Evidence
Folate, B12, B6	Methyl-donor cycle (one-carbon metabolism) — provides methyl groups essential for DNA methylation maintenance and repair	[C/D] — Methyl-donor biochemistry is well-established; direct canine aging-methylation intervention data is absent
Zinc	Cofactor for multiple DNA repair enzymes (zinc-finger nucleases, poly(ADP-ribose) polymerase)	[B]
Polyphenols (resveratrol, EGCG)	Proposed epigenetic modulation via sirtuin activation and histone deacetylase (HDAC) inhibition	[D] — In-vitro data only
Spermidine	Autophagy/epigenetic regulation cross-talk; associated with longevity in rodent and observational human studies	[C/D]

Practical Translation (Editorial)

Epigenetic clocks are the most promising aging biomarker in canine geroscience. Commercial canine biological-age tests are emerging. Clinical utility will depend on standardization, longitudinal validation, and the ability to demonstrate that biological age changes in response to intervention. [B]
Genomic integrity is currently more of a monitoring domain than an intervention target. Unlike inflammation or metabolic health, there are no well-validated nutritional interventions that meaningfully alter DNA repair rates or methylation drift in dogs. The primary "intervention" is reducing upstream sources of genomic damage — oxidative stress, chronic inflammation, and metabolic dysregulation.
Cancer risk assessment remains breed-specific and clinical. Golden Retrievers, Bernese Mountain Dogs, Flat-Coated Retrievers, Boxers, Rottweilers, and Scottish Terriers all carry elevated cancer predispositions that reflect genomic vulnerability. Geroscience provides context but does not replace breed-appropriate cancer screening protocols.

Common Owner Misinterpretations

"Telomere supplements make my dog younger." No supplement has been shown to meaningfully extend telomeres in dogs. Even if one could, the relationship between telomere length and functional aging is far more complex than popular media suggests. Telomere extension also carries theoretical cancer risk by enabling unlimited cell replication.

"A DNA methylation test tells me my dog's real age." Epigenetic clocks estimate biological age with meaningful but imperfect accuracy. They are powerful population-level research tools and are emerging as individual biomarkers — but a methylation-age result does not replace a comprehensive geriatric veterinary assessment. A dog with a "young" methylation age can still have advanced CKD or OA.

Where Geroscience Does NOT Replace Diagnosis

Cancer — the ultimate consequence of genomic instability — requires oncologic management. Breed-specific screening, early detection, and treatment planning are clinical, not nutritional, domains.
Heritable genetic diseases (breed-specific) require genetic testing, responsible breeding guidance, and disease-specific medical management.
Mutagenic exposures (toxins, radiation) require toxicologic assessment and emergency veterinary care.

System 6: Organ-System Reserve & Functional Capacity

The Biology

Organ-system reserve is the integrated output of all five preceding control systems. It is what the dog — and the owner — actually experience: the remaining functional capacity of the kidneys, liver, heart, brain, muscles, and joints to handle the demands of daily life and respond to physiological stress.

The "Comfortspan" concept: The clinically relevant target in canine geroscience is not just lifespan but healthspan — the years of life during which the dog maintains functional independence, comfort, freedom from chronic pain, cognitive engagement, and normal mobility. We use the term "Comfortspan" to describe this specific outcome.

The subclinical gap: Reserve capacity declines for years — sometimes decades — before clinical disease emerges. A dog may lose 65–75% of nephron function before serum creatinine rises above the reference range. Cognitive decline is underway neurologically long before owners notice behavioral changes. This gap between subclinical reserve depletion and clinical disease is where proactive geroscience has its greatest impact.

Canine Organ-System Priorities

Musculoskeletal (OA, sarcopenia, mobility): Osteoarthritis is the leading cause of chronic pain and mobility loss in aging dogs. Radiographic evidence of OA is present in >60% of dogs over 7 years, and the true prevalence is likely higher. Joint-support nutrition (omega-3 EPA/DHA, glucosamine, chondroitin, UC-II collagen, green-lipped mussel) is one of the most evidence-supported applications in veterinary nutraceuticals. [A/B]

Sarcopenia (age-related muscle loss) is an under-recognized contributor to frailty, reduced functional independence, impaired thermoregulation, and increased injury risk. Protein adequacy — and increasingly, leucine-enriched protein sources to stimulate mTOR-mediated muscle protein synthesis — is a critical nutritional consideration in senior dogs. [B]

Cognitive (Canine Cognitive Dysfunction — CCD): CCD prevalence increases sharply after age 8–10, affecting an estimated 28% of dogs aged 11–12 and 68% aged 15–16. Beta-amyloid plaque accumulation in canine brains closely parallels Alzheimer's pathology in humans — making dogs one of the best natural models for cognitive aging research. Nutritional strategies with evidence include MCT (medium-chain triglyceride) supplementation (providing ketone bodies as alternative brain fuel bypassing impaired glucose metabolism), DHA, phosphatidylserine, and antioxidant combinations. [A — Pan et al., 2010 (MCT diet trial); B — observational data on CCD progression]

Cardiac (DMVD, DCM): Degenerative mitral valve disease (DMVD) affects >30% of small-breed dogs by age 10 and is the most common acquired cardiac disease in dogs overall. Large and giant breeds face dilated cardiomyopathy (DCM). Nutritional inputs — taurine (critical for certain DCM-susceptible breeds), L-carnitine, CoQ10, and omega-3 EPA/DHA — have varying levels of evidence for cardiac support. [B/C]

Renal: While CKD is less clinically dominant in dogs than in cats, it does occur — particularly in predisposed breeds. SDMA-based early detection and IRIS staging guide clinical management. Nutritional support centers on phosphorus management, omega-3 supplementation (renal-protective anti-inflammatory effect), and antioxidant support. [A/B]

Hepatic: The liver has remarkable regenerative capacity, but chronic hepatopathies (breed-specific copper-storage disease in Bedlington Terriers, Labrador Retrievers, and others; chronic hepatitis; neoplasia) erode functional reserve. S-adenosylmethionine (SAMe), silybin/silymarin, vitamin E, and ursodeoxycholic acid are used with variable evidence. [B/C]

Key Nutritional Inputs (Organ-System Reserve)

Target	Primary Inputs	Evidence
Joints / muscle	EPA/DHA, UC-II collagen, glucosamine/chondroitin, MSM, green-lipped mussel, adequate high-quality protein (≥25% of calories), leucine-enriched sources	[A/B]
Brain	MCTs (C8 caprylic / C10 capric acid), DHA, phosphatidylserine, antioxidant combination (Vit E + C + Se + carotenoids), B-vitamins	[A] (MCT diet for CCD) / [B/C] (individual components)
Heart	Taurine, L-carnitine, CoQ10, EPA/DHA	[B/C] (taurine for specific DCM: [A])
Kidney	Phosphorus management, EPA/DHA, antioxidants, hydration support	[A/B]
Liver	SAMe, silybin (milk thistle active), vitamin E	[B/C]

Formulation Crosswalk

How the LPL-01 formulation maps across all six aging control systems and organ targets — a unified crosswalk:

This crosswalk consolidates every active ingredient across Hollywood Elixir (HE) and Pet Gala (PG) into a single reference showing multi-system coverage and evidence grades per system. The table is divided into three parts: (A) LPL-01 actives in Hollywood Elixir, (B) LPL-01 actives in Pet Gala, and (C) scientifically significant ingredients that are NOT in the current LPL-01 formulation, retained here as comparative context because they appear in the geroscience literature and are referenced throughout this document. Absence from the formulation is a scope decision, not an absence of evidence.

PART A — Hollywood Elixir Actives

HE Active (dose/sachet)	System 1 (Metabolic)	System 2 (Inflammaging)	System 3 (Oxidative)	System 4 (Senescence)	System 5 (Genomic)	System 6 (Organ Reserve)	Evidence Range
NR (Nicotinamide Riboside) 60 mg	SIRT1/SIRT3 NAD⁺ axis; AMPK indirect via NAMPT upregulation [C/D]	SIRT1-mediated NF-κB deacetylation; SASP attenuation via NAD⁺/SIRT6 [C/D]	Mitochondrial ROS reduction via Complex I efficiency [C/D]	SIRT6-mediated DNA damage response; PARP-1 NAD⁺ supply; SASP amplitude reduction [C/D]	SIRT6/PARP-1 activation; telomere protection via SIRT6 [C/D]	Systemic cellular energy supply; cardiac/neuronal NAD⁺ restoration [C/D]	[C/D]
Niacin (Vitamin B3) 2 mg	Preiss-Handler NAD⁺ biosynthesis pathway — contributes to NAD⁺ pool [B/C]	—	—	—	One-carbon cycle substrate balance [C/D]	Neuronal metabolic cofactor [B/C]	[B/C]
Riboflavin (Vitamin B2) 0.5 mg	FAD/FMN cofactor for ETC Complexes I and II — metabolic efficiency [B/C]	—	GSH reductase cofactor — maintains reduced glutathione pool [B]	—	FAD-dependent DNA repair enzyme support [C/D]	Cellular energy metabolism [B/C]	[B]
Vitamin B6 1 mg	PLP cofactor: transsulfuration → cysteine → GSH [B]	—	—	—	One-carbon methylation cycle: serine hydroxymethyltransferase cofactor [C/D]	Neuronal neurotransmitter synthesis [B/C]	[B]
Vitamin B12 0.25 mg	—	—	—	—	Methyl-cobalamin: direct methyl donor for homocysteine remethylation; maintains SAM:SAH ratio for DNMT activity [C/D]	Neuronal myelin synthesis; cognitive protection [B/C]	[B/C]
CoQ10 40 mg	ETC Complex I–II bridge: reduces electron leak at source; improves metabolic efficiency [C]	—	Mitochondrial ROS source attenuation; ubiquinol — lipid-phase antioxidant [C]	Mitochondrial membrane potential maintenance; anti-apoptotic [C/D]	—	Cardiac: myocardial ETC support; CoQ10 declines with aging and DMVD in dogs [C]	[C]
Glutathione 50 mg	—	Attenuates NF-κB activation threshold via redox regulation [C/D]	Direct intracellular GSH supply: master antioxidant; lipid hydroperoxide neutralization; protein oxidation defense [C/D]	Reduces oxidative-stress-driven senescence entry [C/D]	DNA oxidative lesion prevention via GSH-GPx axis [C/D]	Multi-organ: hepatic, renal, neuronal GSH support [C/D]	[C/D] (oral bioavailability in dogs: PK2/PK3 — systemic delivery uncertain; liposomal/reduced forms show improving evidence)
Astaxanthin 2 mg	—	NF-κB and COX-2 transcriptional attenuation [C]	Membrane-spanning antioxidant; uniquely crosses blood-brain and blood-retinal barriers [C]	Limits oxidative senescence induction [C]	—	Brain: neuroprotection beyond BBB; retinal protection; cardiac antioxidant [C]	[C]
Vitamin C 10 mg	—	—	Aqueous-phase scavenger; regenerates oxidized Vit E; GSH recycling via dehydroascorbate reductase [B]	—	Prolyl/lysyl hydroxylase cofactor — required for collagen triple helix hydroxylation (relevant to tissue homeostasis, not classical genomic) [A]	Collagen synthesis cofactor: ubiquitous connective tissue maintenance [A/B]	[A/B] (collagen synthesis) / [B] (antioxidant)
Vitamin E 15 IU	—	Inflammatory gene modulation via NF-κB suppression; membrane protection during inflammatory stress [B]	Lipid-phase tocopherol: terminates lipid radical chain reactions; primary membrane peroxidation defense [B]	—	—	Hepatoprotection [B/C]; ocular protection [C]	[B]
Resveratrol 15 mg	SIRT1 allosteric modulation; mild AMPK engagement via LKB1 pathway [C/D]	NF-κB p65 deacetylation via SIRT1; COX-2 suppression; anti-inflammatory cytokine modulation [C/D]	Indirect via SIRT1/Nrf2 pathway; radical scavenger [C/D]	SIRT1-mediated p21/p53 pathway modulation; anti-SASP [C/D]	SIRT1 histone deacetylation: H3K9/H4K16 epigenetic maintenance [C/D]	Cardiac: SIRT1-AMPK cardioprotection; canine CVD review data [C/D]	[C/D] (rapid hepatic conjugation limits systemic bioavailability; canine PK3)
Quercetin 25 mg	Mild AMPK activation in cell models [C/D]	NF-κB/IKK inhibition; NLRP3 inflammasome suppression; mast-cell stabilization [C/D]	—	Modest senolytic via BCL-2/BCL-XL inhibition (rodent; dose-dependent; 25 mg maintenance dose is sub-therapeutic for senolytic vs. anti-inflammatory application) [D]	NRF2-pathway epigenetic modulation; Dnmt3 regulation [D]	—	[C/D]
Beta Glucans 50 mg	—	Dectin-1/TLR-4-mediated innate immune training; promotes tolerogenic macrophage polarization; NK cell activation; SASP-mitigating innate calibration [A/B]	—	—	—	Immune system reserve: vaccination response support in senior dogs; anti-infective innate competence [B]	[A/B] (innate immune training)
Reishi Mushroom 25 mg	—	Beta-glucan/triterpenoid dual mechanism: NF-κB modulation + innate immune regulation; NK cell and macrophage calibration [B]	—	—	—	Immune-system reserve [B]; adaptogenic stress-response support [C]	[B]
Spirulina 50 mg	—	Phycocyanin: COX-2/NF-κB modulation; pro-resolving lipid mediator support [C]	Direct radical scavenging; Nrf2 upregulation via phycocyanin [C]	Limits oxidative senescence-entry triggers [C]	—	—	[C]
Blueberry Powder 50 mg	—	Anthocyanins: NF-κB and COX-2 attenuation; NLRP3 suppression [C]	Polyphenol radical scavenging; Nrf2 induction [C]	Limits oxidative senescence induction [C]	—	Cognitive: BDNF upregulation; neuroprotection; aged beagle supplementation data [C]	[C]
Whey Protein Isolate 250 mg	mTORC1 activation via leucine sensing — anabolic signaling for protein synthesis [B]	—	GSH substrate: cysteine precursor from whey fraction [B/C]	—	—	Musculoskeletal: leucine-rich BCAA for mTORC1-dependent muscle protein synthesis; sarcopenia prevention [B]	[B]

PART B — Pet Gala Actives

PG Active (dose/sachet)	System 1 (Metabolic)	System 2 (Inflammaging)	System 3 (Oxidative)	System 4 (Senescence)	System 5 (Genomic)	System 6 (Organ Reserve)	Evidence Range
Omega 3-6-9 blend 150 mg (EPA/DHA + GLA + LA)	Insulin sensitivity via cell membrane fluidity and PPAR-gamma activation [A/B]	Resolvin E1/D1/D2 and protectin D1/D3 precursors — the primary formulation anchor for SPM production; DHA competes with AA at LOX/COX [A]	EPA/DHA membrane structural protection; reduces lipid peroxidation susceptibility [B]	—	—	Joint: [A] by 72-trial meta-analysis; Cardiac [B]; Renal [B]; Cognitive (DHA) [B/C]	[A] (inflammaging, joint) / [A/B] (metabolic) / [B] (cardiac, renal, oxidative)
Omega-7 (Palmitoleic Acid) 50 mg	Lipokine signaling: improves insulin sensitivity; suppresses hepatic lipogenesis via PPAR-alpha [C]	Anti-inflammatory adipokine modulation; NF-κB attenuation [C]	—	—	—	Epithelial/mucosal tissue maintenance; cardiovascular lipid modulation [C]	[C]
L-Carnitine 20 mg	Direct LCFA beta-oxidation substrate (CPT-I/CPT-II shuttle); AMP:ATP elevation → indirect AMPK activation [B/C]	—	Mitochondrial membrane stabilization; reduces mitochondrial ROS from incomplete beta-oxidation [C]	—	—	Cardiac: ~60% of myocardial energy from LCFA; DCM link in susceptible breeds [A/B]; Skeletal muscle energy [B/C]	[A/B] (cardiac DCM-specific) / [B/C] (systemic beta-oxidation)
Zinc (chelated) 1.5 mg	—	—	Cu/Zn-SOD structural cofactor; enzymatic superoxide dismutation [B]	—	OGG1 (8-oxoguanine repair), PARP-1 (nick-sensing/repair), p53 (genomic guardian) — three critical zinc-finger DNA repair proteins [B]	Multi-organ: immune function; wound healing; insulin storage [B]	[B]
Marine Collagen Peptides 500 mg	—	—	—	—	—	Joint/dermal ECM: pre-formed proline/hydroxyproline/glycine (~57% of collagen molecule by weight); bypasses de novo amino acid synthesis for fibroblast collagen production [B]	[B]
Hydrolyzed Whey Protein 250 mg	mTORC1 via leucine [B]	—	Cysteine for GSH synthesis [B/C]	—	—	Musculoskeletal; coat protein supply [B]	[B]
Beef Gelatin 200 mg	—	—	—	—	—	Joint: proline-rich structural protein for connective tissue; complementary collagen precursor pool [B]	[B]
Bone Broth 100 mg	—	—	—	—	—	Joint/wound healing: mineral matrix (calcium, phosphorus, magnesium, trace minerals) for extracellular matrix and wound-healing cascade [B/C]	[B/C]
Hyaluronic Acid 50 mg	—	—	—	—	—	Joint: GAG hydration — primary hygroscopic macromolecule of the dermis and synovial fluid [B]	[B]
MSM (methylsulfonylmethane) 100 mg	—	Anti-inflammatory: inhibits NF-κB and MAPK signaling [C]	Glutathione synthesis support via bioavailable sulfur donation [C]	—	—	Joint: organic sulfur for proteoglycan and collagen synthesis; articular cartilage maintenance [C]	[C]
Biotin 50 mcg	Carboxylase enzyme cofactor: acetyl-CoA carboxylase (fatty acid synthesis), pyruvate carboxylase (gluconeogenesis) [A/B]	—	—	—	—	Epithelial/keratin: keratinocyte carboxylase activity [A] (canine-specific Grade A evidence for keratin/nail integrity)	[A] (keratin/coat specific) / [B] (metabolic carboxylase)
Silica 10 mg	—	—	—	—	—	Connective tissue: promotes collagen cross-linking via prolyl hydroxylase activity; dermal matrix structural stabilization [C]	[C]
Ceramides 8 mg	—	—	—	—	—	Epithelial: direct lamellar constituent of the stratum corneum intercellular lipid matrix; barrier integrity and TEWL reduction [C]	[C] (oral ceramide bioavailability PK2)

PART C — ⊘ Scientifically Significant Ingredients NOT in LPL-01 Formulation

These ingredients are referenced throughout this document as comparative geroscience context. They are not in Hollywood Elixir or Pet Gala. Their absence is a formulation scope decision. They are documented here to ensure the framework presents a complete scientific picture and to prevent any reader from concluding that their omission reflects ignorance of the evidence.

⊘ Non-LPL-01 Active	System 1	System 2	System 3	System 4	System 5	System 6	Why Not in LPL-01	Evidence
⊘ Selenium	—	—	GPx family cofactor (4 selenoenzyme isoforms): primary enzymatic defense against lipid hydroperoxides	—	—	—	Not currently included; selenoprotein pathway covered indirectly by Zinc/SOD and Glutathione	[B]
⊘ NAC (N-acetylcysteine)	—	—	Rate-limiting cysteine donor for GSH synthesis; established veterinary use for acetaminophen toxicity rescue	—	—	Liver: hepatoprotection via GSH restoration	Oral chronic supplementation data limited in dogs; not in current SKU	[C/D] (chronic supplementation)
⊘ Curcumin (bioavailable forms)	—	NF-κB/IKK inhibition + COX-2 suppression; two canine OA RCTs with phytosomal form	Antioxidant [C/D]	—	—	—	Not in current SKU; bioavailability challenges without bioenhancement	[C/D]
⊘ Sulforaphane	—	—	Nrf2 activator (KEAP1 inhibition) → endogenous antioxidant enzyme upregulation	—	—	—	Not in current SKU; feline-safe isothiocyanate; canine data limited	[C/D]
⊘ Fisetin	—	—	—	Most potent flavonoid senolytic in 10-compound screen; 25–50% p16INK4a/p21 clearance in rodent models	—	—	Not in current SKU; no canine efficacy, safety, or PK data	[D]
⊘ Spermidine	mTOR-independent autophagy via EP300 acetyltransferase inhibition	—	—	Autophagy induction and SASP suppression	EP300-mediated histone hypoacetylation pattern associated with longevity	—	Not in current SKU; polyamine metabolism species-specific	[C/D]
⊘ MCTs C8/C10	—	—	—	—	—	Cognitive: Grade [A] in 3 canine CCD RCTs — ketone bodies as alternative brain fuel; strongest single cognitive supplement in dogs	Not in current SKU; requires caloric accounting; dedicated cognitive formulation territory	[A] (canine CCD)
⊘ UC-II (undenatured type II collagen)	—	Oral tolerance via Peyer's patch Treg modulation	—	—	—	Joint: 4 canine RCTs; non-inferior to NSAIDs in 76-dog trial; superior to glucosamine	Not in current SKU; distinct mechanism from hydrolyzed collagen peptides	[A/B]
⊘ Taurine (standalone)	—	—	—	—	—	Cardiac: Grade [A] for reversible DCM in susceptible breeds; mitochondrial membrane stabilizer	Not in current SKU as standalone; whey protein provides biosynthesis precursors	[A] (DCM-specific)
⊘ SAMe	—	—	GSH precursor via transsulfuration	—	Direct DNMT methyl donor; maintains methylation patterns	Hepatoprotection: NF-κB inhibition in canine hepatocytes; liver GSH restoration [B/C]	Not in current SKU; established veterinary hepatology and cognitive application	[B/C]
⊘ Phosphatidylserine	—	—	—	—	—	Brain: membrane fluidity; cognitive support in aged subjects [B/C]	Not in current SKU	[B/C]
⊘ Glucosamine/Chondroitin	—	—	—	—	—	Joint: UDP-GlcNAc precursor — no significant benefit in 72-trial canine OA meta-analysis; superceded by omega-3 and UC-II	Not in current SKU; evidence does not support inclusion	[null] (meta-analysis negative)
⊘ Boswellia serrata	—	5-LOX inhibition via boswellic acids; some positive canine OA data	—	—	—	Joint anti-inflammatory	Not in current SKU	[C]
⊘ Prebiotics / fiber	Glycemic modulation via SCFA/microbiome axis	Gut-immune tone via SCFA → HDAC inhibition → Treg promotion	—	—	—	—	Not in current SKU	[B]

How to read this crosswalk: Part A covers every Hollywood Elixir active; Part B covers every Pet Gala active; Part C documents all non-LPL-01 ingredients that appear in the geroscience literature and throughout this document. Multi-system actives (NR, EPA/DHA, Zinc, B-vitamins, L-Carnitine) demonstrate why the two-product system outperforms either product alone. The evidence range column shows the span from strongest to weakest canine evidence for each active across all six systems.

Key insights:

EPA/DHA (Pet Gala) holds the highest evidence grade across the most systems — the formulation's Grade [A] backbone for inflammaging and joint support
NR (Hollywood Elixir) is the primary NAD⁺/sirtuin axis input, with the broadest theoretical multi-system reach but lowest direct canine evidence (Grade [C/D] across all systems — a reflection of where canine aging science currently sits, not a formulation weakness)
Beta Glucans and Reishi (Hollywood Elixir) are underrecognized in conventional geroscience frameworks but carry Grade [A/B] evidence for innate immune calibration — increasingly understood as a critical parallel mechanism to the resolvin/protectin axis
L-Carnitine (Pet Gala) provides the only Grade [A] cardiac-specific input in the combined system, via its DCM-linked myocardial beta-oxidation mechanism
The ⊘ section shows what the formulation intentionally does not include — some of these (MCTs for CCD, UC-II for joints, taurine for DCM) have stronger canine evidence than some included actives. Their absence represents scope decisions aligned to the daily nutritional support positioning of the products, not evidence gaps

Practical Translation (Editorial)

Organ reserve depletion is subclinical for years. The most impactful veterinary geroscience practice is early, routine screening — catching IRIS Stage 1 CKD (via SDMA), early CCD (via CCDR/DISHAAL), preclinical DMVD (via auscultation + NT-proBNP), and subclinical OA (via gait assessment + owner questionnaire) before they become clinical crises.
Proactive nutrition starts before clinical disease, not after. Waiting until a dog has Stage 3 CKD to adjust phosphorus intake, or until DMVD reaches Stage C to add omega-3s, means years of potential optimization were missed. Nutritional geroscience is inherently preventive.
Sarcopenia deserves more clinical attention than it currently receives. Age-related muscle loss is underdiagnosed because it develops gradually and is often attributed to "normal aging." Muscle Condition Scoring (MCS) at every senior visit, combined with protein-adequacy assessment, should be standard practice. [B]
Multimodal OA management is the standard of care. The combination of pharmacologic (NSAIDs, gabapentin, anti-NGF antibodies), nutritional (omega-3, joint supplements), rehabilitative (physical therapy, hydrotherapy, laser), and environmental (ramps, orthopedic bedding, floor traction) strategies outperforms any single modality. [A/B]

Common Owner Misinterpretations

"My dog is slowing down because of age — nothing can be done." Reduced activity is not an inevitable, untreatable aspect of aging. It is a clinical signal — most commonly of pain (OA), metabolic dysfunction, cognitive decline, or cardiac limitation. All have management options that can substantially improve quality of life.

"Kidney problems happen suddenly." Renal decline is gradual and subclinical for most of its course. By the time clinical signs appear (increased thirst/urination, weight loss, inappetence, vomiting), substantial nephron loss has already occurred. SDMA-based screening detects CKD earlier than creatinine alone. [A]

"Joint supplements replace pain medication." Nutraceuticals (omega-3, UC-II, glucosamine) support joint structure and provide mild anti-inflammatory benefit over weeks to months. They do not provide the acute analgesic effect of NSAIDs, gabapentin, or anti-NGF antibodies. Multimodal pain management — combining multiple approaches — is the standard of care for OA. [A/B]

Where Geroscience Does NOT Replace Diagnosis

CKD Stages 3–4 require medical management: fluid therapy, phosphate binders, erythropoietin, anti-nausea medication, renal-prescription diet. Nutritional geroscience supports early-stage kidney health; it does not treat renal failure.
Congestive heart failure requires pharmacologic intervention: pimobendan, furosemide, ACE inhibitors, spironolactone — per ACVIM staging guidelines.
Advanced CCD with severe behavioral disturbance may benefit from selegiline (Anipryl) or other pharmacotherapy alongside nutritional cognitive support.
Orthopedic conditions (cranial cruciate ligament rupture, femoral head necrosis, fractures, severe OA) require surgical evaluation and comprehensive medical pain management.
Cancer — the leading cause of death in many breeds — requires oncologic assessment and treatment.

Clinical Vignette

Case provided by JoAnna Pendergrass, DVM

A 7-year-old Labrador Retriever named Rex has a veterinary appointment. His owner tells the veterinarian that Rex has been slowing down recently. He is in good spirits but struggles to get up, is reluctant to go up the stairs, and cannot play like he used to. Given Rex's age and breed, the veterinarian suspects that Rex is beginning to show signs of osteoarthritis.

The vet performs a physical exam, paying close attention to Rex's hip mobility. They observe a reduced range of motion in the hip joints, along with some crepitus and obvious discomfort. Walking around the exam room, Rex is visibly stiff and slow. He is also slightly overweight, with a body condition score of 6/9.

X-rays of Rex's hips show a degeneration of the hip joint, with bony changes that indicate osteoarthritis. Bloodwork and a urinalysis show that Rex is otherwise healthy.

The vet recommends a multimodal approach to managing Rex's osteoarthritis, which includes a weight-loss plan (increased physical activity and reduced caloric intake), pain medication, supplementation, and physical therapy. Supplementation recommendations include omega-3 fatty acids to reduce inflammation, along with other joint-supporting nutraceuticals such as glucosamine, chondroitin, and green-lipped mussel.

Physical therapy includes at-home exercises, such as passive range-of-motion exercises and massage, as well as veterinary rehabilitation.

This approach to managing Rex's osteoarthritis is comprehensive yet reactive, developed and implemented only after clinical signs are already present.

Clinical Perspective (DVM Co-Author)

JoAnna Pendergrass, DVM

The visible signs of aging that veterinarians observe in clinical practice are outward manifestations of the biological aging processes occurring at the cellular and molecular levels.

One of the hallmarks of aging in dogs is nutrient-sensing and metabolic regulation. For example, the growth hormone/insulin-like growth factor-1 (GH/IGF-1) pathway plays a critical role in regulating blood insulin levels. Obese dogs can have disrupted signaling in this pathway, leading to progressive insulin resistance and chronically elevated blood insulin levels.

Inflammaging, chronic low-grade inflammation, is another hallmark of aging in dogs that manifests clinically. This chronic inflammation is not only evident on bloodwork but also leads to an overactive immune system, contributing to allergies (e.g., food, environmental) and autoimmune disease. Inflammaging also contributes to periodontal disease, a condition affecting the structures that surround and support the teeth, with clinical signs such as tooth decay, bleeding gums, and bad breath.

Cellular senescence also has clinical downstream effects. Senescent cells release substances, such as pro-inflammatory cytokines, that damage organs like the kidney and liver; this damage becomes evident through signs of organ dysfunction and abnormal bloodwork.

Stem-cell exhaustion that occurs in aging leads to clinical signs such as muscle loss and impaired wound healing.

Genomic instability due to factors such as oxidative stress and ultraviolet radiation plays a major role in cancer development in dogs. In older dogs, cellular repair mechanisms become less effective at repairing DNA damage, leading to accumulated damage and, potentially, cancer.

Pet parents may hold common misconceptions about aging in dogs, including those described below:

"Dogs inevitably gain weight as they age." Although dogs commonly gain weight as they age due to reduced physical activity, this weight gain is not inevitable. With an age-appropriate diet and regular physical activity, dogs can maintain a healthy weight throughout their lives.
"It's normal for older dogs to slow down." As with weight gain, slowing down isn't inevitable in a dog's older years. Decreased mobility is an outward symptom of medical conditions, such as arthritis, that make movement more difficult. Managing the underlying condition can improve mobility and keep older dogs moving.
"Supplements can replace a poor diet." Supplements are not meant to supply all a dog's nutritional needs. Rather, they are most effective when accompanied by a balanced, nutritionally complete diet and an overall healthy lifestyle. A veterinarian can identify the specific supplements a dog needs to support them through the aging process.
"Supplements are a substitute for veterinary care." Supplements support a dog's health, but they are not meant to replace veterinary care. Chronic diseases like diabetes require regular veterinary care for effective management.

Risk, Uncertainty, and the Limits of Current Knowledge

Intellectual honesty requires acknowledging what canine geroscience does not yet know and where current tools fall short.

Rapamycin: Promise and Limitations in Dogs

Rapamycin (sirolimus) is the most robust pharmacologic lifespan-extending intervention in mammalian models. It inhibits mTOR complex 1 (mTORC1), promoting autophagy, reducing age-related pathology, and extending both healthspan and lifespan in genetically diverse mice (Harrison et al., 2009). [C]

The Dog Aging Project's TRIAD (Test of Rapamycin in Aging Dogs) trial is the landmark companion-animal geroscience study — a multi-site, double-blind, placebo-controlled RCT evaluating low-dose, intermittent rapamycin in middle-aged large-breed dogs. Preliminary data on cardiac function is encouraging (improved diastolic function in treated dogs). [A — trial in progress; preliminary results published]

Limitations and unknowns specific to dogs:

Immunosuppressive risk. Rapamycin was originally developed as a transplant immunosuppressant. At what dose and schedule does geroprotective benefit in dogs diverge from immunosuppressive risk? This threshold is not yet defined.
Dose-duration optimization. Intermittent, low-dose protocols (as used in the TRIAD trial) appear to mitigate side effects — but optimal regimens for different breed sizes and ages are unknown.
Long-term safety. Multi-year rapamycin use in healthy dogs has not been studied. Potential concerns include impaired wound healing, glucose and lipid metabolic effects, and mucosal toxicity.
Breed-size pharmacokinetics. A Chihuahua and a Mastiff process drugs differently. Scaling rapamycin dosing across the 2–80+ kg range of domestic dogs is non-trivial.
Not a supplement. Rapamycin is a prescription drug requiring veterinary oversight, regular monitoring, and informed-consent discussion with the owner. It is mentioned here for scientific completeness and context, not as a nutraceutical recommendation.

Nutraceutical Outcome Gaps

An honest assessment of the current state of nutraceutical geroscience in dogs:

Omega-3 fatty acids (EPA/DHA) have the strongest evidence base across multiple domains (anti-inflammatory, joint-supportive, renal-protective, neuro-supportive, cardiac-supportive). However, even this well-studied intervention has been evaluated primarily via surrogate endpoints (inflammatory markers, clinical scores, imaging). No canine omega-3 RCT has used lifespan as a primary endpoint. [A/B for surrogate endpoints; no lifespan RCT]
Antioxidant combinations have some clinical trial support for specific conditions (CCD dietary trials, renal-supportive formulations) but have not demonstrated lifespan extension in dogs. [B/C]
Senolytics (fisetin, quercetin) are rodent-stage science applied to dogs without species-specific validation. [D]
NAD+ precursors (NMN, NR) are in early-phase human clinical trials; canine-specific data is essentially absent. [D]
Caloric restriction is the most robust proven longevity intervention in dogs (Kealy et al., 2002: +1.8 years median lifespan) — but it is a dietary management strategy, not a supplement. [A]

The Lifespan vs. Healthspan Distinction

Most geroscience claims for nutraceuticals are actually healthspan claims — improved comfort, reduced disease markers, better functional scores, slower decline trajectories — not proven lifespan extension. Healthspan improvement is genuinely important and valuable. But it is not the same thing as "living longer." We should be precise about which outcome we are describing, and we should not allow healthspan data to be marketed as lifespan data.

Boundary Statement

Where LPL-01 sits in the canine aging-care hierarchy — and where it does not:

Domain	Veterinary Domain (Required)	LPL-01 Nutritional Support Domain (Adjunctive)	Boundary
Metabolic regulation	Diabetes diagnosis and insulin therapy; Cushing's/hypothyroid management; obesity-related disease treatment	Omega-3 for insulin sensitivity support; fiber for glycemic modulation; caloric-moderation compatible formulation	Nutrition supports metabolic health; it does not treat diabetes, endocrine disease, or metabolic emergencies
Inflammaging management	IMHA, ITP, sepsis, pancreatitis, IBD — all require medical/specialist intervention	EPA/DHA (PG) — resolvin/protectin precursors for pro-resolving mediation; quercetin and resveratrol (HE) — NF-κB/NLRP3 transcriptional modulation; beta-glucans and reishi (HE) — innate immune calibration	Nutrition supports inflammatory tone; it does not treat immune-mediated, infectious, or neoplastic inflammatory disease
Oxidative emergency	Toxin ingestion, reperfusion injury, heat stroke, hemolytic crisis	Glutathione (HE) — direct GSH supply; vitamins C and E (HE) — aqueous and lipid phase antioxidant reserve; astaxanthin (HE) — BBB-crossing membrane antioxidant; CoQ10 (HE) — mitochondrial ROS attenuation; zinc (PG) — SOD metalloenzyme cofactor	Nutrition supports baseline antioxidant capacity; it does not treat acute oxidative emergencies
Cancer	Oncologic assessment, surgery, chemotherapy, radiation, immunotherapy	General nutritional support for quality of life during treatment	Nutrition does not treat, prevent, or slow neoplastic disease. Claims otherwise are not evidence-based.
Organ failure	CKD Stage 3–4 (fluid therapy, phosphate binders); CHF (pimobendan, furosemide); advanced CCD (selegiline)	EPA/DHA (PG) — renal anti-inflammatory and phospholipid support [B]; L-carnitine (PG) — cardiac beta-oxidation substrate (myocardial energy support) [B/C]; CoQ10 (HE) — mitochondrial energy for cardiomyocytes [C]; NR (HE) — systemic cellular NAD⁺/energy support [C/D]; blueberry + DHA (HE + PG) — cognitive neuronal support for early CCD [C]	Nutrition supports organ reserve before clinical disease; it does not treat organ failure
Orthopedic disease	CCL rupture, fractures, severe OA requiring surgery or aggressive pharmacologic pain management	EPA/DHA (PG) — Grade [A] in 72-trial meta-analysis: the strongest single nutraceutical for canine OA; collagen peptides, HA, MSM (PG) — structural matrix substrate supply [B]; quercetin (HE) — anti-inflammatory tone as part of multimodal management [C/D]	Nutrition provides mild, cumulative joint support; it does not replace NSAIDs, anti-NGF antibodies, or surgical intervention
Normal aging (no disease present)	Geriatric screening to rule out subclinical disease	Full-spectrum multi-system support across all six aging control systems	This is the primary domain where nutritional geroscience operates independently — supporting normal biological function when no disease is present

Summary principle: LPL-01 formulations address the nutritional-support layer of canine geroscience. They supply substrates for normal biological function across the six aging control systems. When disease is present, veterinary diagnosis and treatment are primary. Nutritional support is adjunctive to, not a substitute for, medical care.

The honest position: The most impactful canine geroscience interventions are (1) maintaining lean body condition [A], (2) regular veterinary screening [A/B], (3) appropriate exercise [B], and (4) dental care [B]. Nutritional supplementation ranks below all of these in evidence strength for overall aging outcomes. The formulation supports — it does not lead — the geroscience strategy.

When to Escalate to a Veterinarian

JoAnna Pendergrass, DVM

Supportive measures such as a healthy diet, regular exercise, and geroprotective nutrition play important roles in proactively managing a dog's health as they age. However, there are times when those supportive measures are not enough, and veterinary care is needed.

For example, a dog with severe arthritis in their hip joints will need more than omega-3 fatty acid supplementation to manage their condition. Veterinary care would include pain medication and possibly surgery if the arthritis-related bony degeneration is advanced.

Chronic diseases such as kidney disease and diabetes require constant veterinary monitoring. With kidney disease, regular bloodwork and urinalysis are needed to assess kidney function, and a specialized kidney diet is needed to reduce the kidneys' workload. Diabetes requires insulin therapy, along with close monitoring of blood sugar levels and, if needed, adjustments to the insulin dose.

Even if an escalation to veterinary care is warranted, geroprotective strategies, such as physical activity and geroprotective nutrition, can still be used to support the management of chronic conditions in dogs.

Sources

Foundational Geroscience

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. "The Hallmarks of Aging." Cell. 2013;153(6):1194–1217. [Updated: López-Otín C, et al. "Hallmarks of aging: An expanding universe." Cell. 2023;186(2):243–278.]
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. "Inflammaging: a new immune–metabolic viewpoint for age-related diseases." Nat Rev Endocrinol. 2018;14(10):576–590.
Kennedy BK, Berger SL, Brunet A, et al. "Geroscience: linking aging to chronic disease." Cell. 2014;159(4):709–713.

Canine Aging Research

Kealy RD, Lawler DF, Ballam JM, et al. "Effects of diet restriction on life span and age-related changes in dogs." J Am Vet Med Assoc. 2002;220(9):1315–1320.
Creevy KE, Akey JM, Kaeberlein M, Promislow DEL; Dog Aging Project Consortium. "An open science study of ageing in companion dogs." Nature. 2022;602:51–57.
Urfer SR, Kaeberlein TL, Mailheau S, et al. "A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs." GeroScience. 2017;39(2):117–127.
Greer KA, Canterberry SC, Murphy KE. "Statistical analysis regarding the effects of height and weight on life span of the domestic dog." Res Vet Sci. 2007;82(2):208–214.
Pan Y, Larson B, Araujo JA, et al. "Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs." Br J Nutr. 2010;103(12):1746–1754.
Bauer JE. "Therapeutic use of fish oils in companion animals." J Am Vet Med Assoc. 2011;239(11):1441–1451.

Comparative & Translational

Harrison DE, Strong R, Sharp ZD, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460(7253):392–395.
Kaeberlein M, Creevy KE, Promislow DEL. "The Dog Aging Project: Translational geroscience in companion animals." Mamm Genome. 2016;27(7–8):279–288.
Watson TDG. "Diet and skin disease in dogs and cats." J Nutr. 1998;128(12 Suppl):2783S–2789S.

LPL-01™ Companion-Care Standard · La Petite Labs Canine Geroscience · Last revised: April 2026 Veterinary co-author: JoAnna Pendergrass, DVM

Funding & Industry Disclosures

Several landmark canine-aging studies cited in this framework were funded by pet-food manufacturers.

Kealy RD, Lawler DF, Stowe HD et al. 2002 (JAVMA 220:1315) — lifelong diet-restriction Labrador study: Nestlé Purina research (authors were Purina scientists; the diet tested is a Purina formulation). Still the foundational canine geroscience lifespan trial.
Pan Y, Larson B, et al. 2010 (Br J Nutr) — MCT diet in aged dogs: Nestlé Purina research (formed the scientific basis for Purina ProPlan Bright Mind / Neurocare).
López-Otín C et al. 2013 / 2023 (Cell, Hallmarks of Aging) — academic, but several co-authors on the 2023 update hold equity in longevity biotechs (Life Length, Altos Labs, Rejuveron).